Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.

Project description

Improving immune-oncology treatments efficacy

Immunotherapy offers hope in the fight against cancer, but with a response rate of only 10-20 % in solid tumours, its potential remains underutilised. Predicting patient responses to this treatment is an urgent medical need that current methods inadequately address. The EIC-funded Improving IO (IOO) project will develop a validated multiplexed biomarker assay based on proprietary bio-imaging technology. Although scientifically validated, it requires further clinical validation for regulatory certification. This assay could significantly improve the efficacy of immune-oncology treatments by accurately predicting patient responses to immune checkpoint inhibitors, which underpin 90 % of current therapies. If successful, it could be adopted in hospitals worldwide, potentially doubling survival rates for lethal tumours such as lung cancer.

Objective

Immunotherapy is a beacon of hope in cancer's battle, but with a 10-20% response rate in solid tumors, its potential is untapped. Predicting patient responses to treatment, which current methods are ill-equipped for, is an urgent unmet medical need. Our project stands for industrializing our analytically validated multiplexed protein-function based biomarker assay (IOO), currently TRL6, which is based on our proprietary bio-imaging technology. Whilst scientifically validated, we need further clinical validation to obtain increased datasets required for regulatory certification for clinical deployment. This assay could triple the efficacy of currently available immune-oncology treatments by accurately predicting patient response to immune checkpoint inhibitors - the basis of 90% of current immuno-oncology therapies. If successful, we will bring this transformative solution to hospitals worldwide. The upshot could be game-changing: doubling survival rates for high-prevalence, lethal tumors like lung cancer.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

FASTBASE SOLUTIONS SOCIEDAD LIMITADA
Net EU contribution
€ 2 496 112,50
Address
C/ ASTONDO BIDEA - PARQUE TECNOLOGICO DE BIZKAIA, KABI 612
48160 DERIO BIZKAIA
Spain
SME
Yes
Region
Noreste País Vasco Bizkaia
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 565 875,00